Showing results (351-360 of 700) with videos related to

Sort By:
Pageof 70
British Journal of Haematology|August 9, 2017
Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemiaJonas Paludo, Jithma P Abeykoon, Shaji Kumar, et al.
JACC. Cardiooncology|April 22, 2026
Cardiac Biomarker Complete Response in AL Amyloidosis: Characteristics, Cardiac Recovery, and Survival of 63 PatientsEli Muchtar, Susan Geyer, Angela Dispenzieri, et al.
Transplantation and Cellular Therapy|August 8, 2022
Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction TherapyMohammad Ebraheem, Shaji K Kumar, Angela Dispenzieri, et al.
Annals of Hematology|April 4, 2018
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemiaJonas Paludo, Jithma P Abeykoon, Amanda Shreders, et al.
Blood|October 6, 2016
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomibShaji K Kumar, Betsy R LaPlant, Craig B Reeder, et al.
Blood Advances|June 23, 2022
Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosisEli Muchtar, Morie A Gertz, Betsy R LaPlant, et al.
Mayo Clinic Proceedings|August 8, 2015
Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus StatementAngela Dispenzieri, Francis Buadi, Shaji K Kumar, et al.
Circulation. Cardiovascular Imaging|May 13, 2018
Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain AmyloidosisPaolo Milani, Angela Dispenzieri, Christopher G Scott, et al.
American Journal of Hematology|June 2, 2017
The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myelomaToshi Ghosh, Wilson I Gonsalves, Dragan Jevremovic, et al.
Blood Cancer Journal|January 9, 2020
Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysisRahma Warsame, Betsy LaPlant, Shaji K Kumar, et al.
Pageof 70